- Went public, Mar 2023
- Raised $9M funding round, Jun 2016
About
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines to help people with a range of oncologic and dermatologic diseases. The companys technology targets the VDAC/HK2 system unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. Vidacs lead drug, VDA-1102, has successfully completed a phase 2b clinical trial in actinic keratosis (AK) as an investigational new drug under the FDA and is currently in a phase 2a clinical trial in CTCL in Israel. The company is also developing VDA-1275, a potent small-molecule new chemical entity that selectively modulates the novel VDAC/HK2 mechanism of action. It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for the VDAC/HK2 system over the VDAC/HK1 system. VDA-1275 is chemically unrelated to VDA-1102 and presents a different set of pharmacokinetic characteristics. It is being developed as a systemic drug for the treatment of solid tumors. Vidac was founded by Professor Max Herzberg. The company has licensed part of its technology from Tel Aviv University and Ben Gurion University.
Funding history · 1 round · $9.0M total
Q&A
- What is Vidac Pharma's primary focus?
- Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for oncologic and dermatologic diseases, particularly skin cancer treatment.
- When was Vidac Pharma founded?
- Vidac Pharma was founded in January 2012 by Professor Max Herzberg.
- What is the current employee count for Vidac Pharma?
- Vidac Pharma has an employee count in the 1-10 range.
- What is Vidac Pharma's lead drug candidate?
- Vidac Pharma's lead drug is VDA-1102, which has completed a phase 2b clinical trial for actinic keratosis and is currently in a phase 2a clinical trial for CTCL.
- What is Vidac Pharma's status as of March 2023?
- In March 2023, Vidac Pharma became a public company, listed on the Hamburg Stock Exchange.
- What is the total amount of funding Vidac Pharma has raised?
- Vidac Pharma has raised a total of $9,000,000 USD.
- Which investors participated in Vidac Pharma's funding round in June 2016?
- In June 2016, Vidac Pharma raised $9,000,000 USD with participation from.
- What is the mechanism of action for Vidac Pharma's technology?
- Vidac Pharma's technology targets the VDAC/HK2 system, which is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting healthy tissue.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vidacpharma.com |
|---|---|
| linkedin.com/company/3121139 |
Identifiers & details
| Founded | 2012-1 |
|---|---|
| Employees (exact) | 9 |
| Offices | Brookline |
| Status reason | Public on Hamburg Stock Exchange on Mar, 2023 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2023-03 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | vidacpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|